background
airway
prolifer
pseudomona
aeruginosa
bacteria
thought
trigger
cf
exacerb
may
affect
presenc
viral
infect
method
prospect
studi
conduct
adult
cf
p
aeruginosa
sputum
densiti
analyz
stabl
exacerb
post
exacerb
assess
upon
exacerb
sampl
sent
pcr
detect
respiratori
virus
sputum
densiti
p
aeruginosa
patient
viral
infect
versu
without
compar
result
twentytwo
patient
experienc
exacerb
studi
period
associ
viral
infect
chang
sputum
densiti
p
aeruginosa
stabl
exacerb
state
measur
quantit
cultur
pcr
virusassoci
exacerb
result
signific
increas
p
aeruginosa
sputum
densiti
compar
nonvir
exacerb
conclus
sputum
densiti
p
aeruginosa
increas
time
cf
exacerb
influenc
presenc
viral
infect
lung
diseas
cystic
fibrosi
cf
character
chronic
bacteri
airway
infect
punctuat
acut
deterior
term
pulmonari
exacerb
pulmonari
exacerb
defin
clinic
combin
sign
symptom
increas
cough
sputum
purul
dyspnea
weight
loss
cf
exacerb
associ
declin
lung
function
neg
impact
qualiti
life
associ
signific
cost
addit
frequent
exacerb
associ
increas
risk
death
lung
transplant
pathophysiolog
exacerb
remain
unclear
link
clonal
expans
exist
bacteria
rather
acquisit
new
bacteria
hypothes
exacerb
might
caus
increas
airway
bacteria
prolifer
chang
bacteri
phenotyp
studi
found
sputum
bacteri
densiti
decreas
follow
exacerb
patient
improv
clinic
antibiot
find
lead
hypothesi
increas
bacteri
densiti
immedi
time
exacerb
might
contribut
pathophysiolog
exacerb
howev
prospect
studi
investig
hypothesi
rel
lack
viral
infect
thought
trigger
cf
exacerb
though
preval
studi
vari
exacerb
caus
viral
infect
associ
longer
cours
antibiot
worsen
lung
function
addit
patient
virusassoci
exacerb
report
sever
clinic
present
shorter
durat
next
exacerb
nonviru
associ
exacerb
evid
suggest
viral
infect
associ
chang
bacteri
densiti
lung
rel
scanti
studi
adult
patient
cf
chronic
bacteri
infect
viral
infect
associ
small
increas
sputum
bacteri
densiti
time
cf
exacerb
associ
viral
infect
bacteri
burden
also
shown
respiratori
ill
chronic
pulmonari
obstruct
diseas
copd
experiment
rhinoviru
infect
patient
copd
result
increas
sputum
bacteri
densiti
peak
day
postrhinoviru
infect
result
suggest
viral
infect
may
instrument
precipit
secondari
bacteri
infect
object
studi
determin
chang
sputum
densiti
pseudomona
aeruginosa
time
pulmonari
exacerb
compar
stabl
state
addit
want
determin
whether
chang
bacteri
sputum
densiti
affect
presenc
acut
viral
respiratori
tract
infect
twoyear
prospect
observ
studi
adult
cf
patient
evalu
stabl
exacerb
postexacerb
state
subject
recruit
cf
clinic
ottawa
hospit
start
june
follow
april
adult
patient
n
year
confirm
cf
abl
spontan
produc
sputum
histori
chronic
infect
p
aeruginosa
least
posit
sputum
cultur
p
aeruginosa
month
period
studi
entri
recruit
ethic
approv
studi
obtain
ottawa
hospit
research
ethic
board
accord
amend
declar
helsinki
inform
written
consent
obtain
subject
patient
enrol
studi
stabl
reassess
everi
month
visit
patient
provid
sputum
sampl
quantit
bacteri
densiti
assess
rtqpcr
revers
transcript
realtim
polymeras
chain
reaction
viru
detect
episod
worsen
respiratori
symptom
patient
instruct
contact
cf
staff
patient
assess
determin
met
criteria
pulmonari
exacerb
defin
criteria
publish
cystic
fibrosi
foundat
microbiolog
infecti
diseas
consensu
confer
confirm
cf
exacerb
patient
ask
provid
spontan
sputum
sampl
nasopharyng
np
swab
taken
respiratori
viru
assess
patient
treat
antibiot
necessari
ask
return
minimum
day
later
postexacerb
assess
quantit
cultur
process
within
h
collect
special
microbiolog
laboratori
children
hospit
eastern
ontario
per
burn
et
al
use
serial
dilut
dilut
sampl
inocul
onto
macconkey
agar
pseudomona
cetrimid
agar
number
coloni
form
unit
cfu
per
millilit
ml
sputum
determin
coloni
count
sputum
sampl
dilut
steril
dulbecco
phosphat
buffer
salin
dpb
vortex
mix
centrifug
rpm
bring
particul
nucleic
acid
dna
rna
extract
sputum
supernat
use
autom
extract
devic
iprep
life
technolog
carlsbad
ca
final
elut
volum
bacteriophag
viru
zeptometrix
corp
buffalo
ny
ad
sampl
prior
nucleic
acid
extract
amplif
extract
control
previous
publish
exonucleas
probe
assay
target
p
aeruginosa
ecfx
extra
cytoplasm
function
sigma
factor
use
detect
p
aeruginosa
sputum
sampl
realtim
pcr
pcr
perform
volum
pcr
plate
use
taqman
fast
advanc
master
mix
life
technolog
thermocycl
perform
use
thermocycl
life
technolog
fast
mode
initi
second
follow
cycl
twotemperatur
cycl
follow
cycl
threshold
ct
valu
obtain
use
softwar
export
excel
analysi
realtim
pcr
rtqpcr
panel
use
test
np
swab
sputum
sampl
major
viral
respiratori
pathogen
includ
rhinovirus
enterovirus
influenza
b
respiratori
syncyti
viru
rsv
b
human
metapneumoviru
b
parainfluenza
viru
coronaviru
coronaviru
coronaviru
coronaviru
bocaviru
adenovirus
rtqpcr
perform
use
panel
exonucleas
probe
assay
perform
assay
valid
use
molecular
profici
test
specimen
clinic
sampl
manuscript
submit
public
world
journal
pediatr
briefli
assay
mix
taqman
fast
viru
master
mix
life
technolog
nucleic
acid
sampl
place
reaction
volum
plate
life
technolog
thermocycl
perform
use
thermocycl
initi
temperatur
held
min
revers
transcript
follow
cycl
twotemperatur
cycl
follow
ct
valu
obtain
export
excel
analysi
coloni
count
measur
quantit
cultur
analyz
use
log
scale
data
test
normal
coloni
count
pcr
ct
stabl
exacerb
post
exacerb
assess
compar
use
pair
ttest
coloni
count
exacerb
compar
stabl
assess
immedi
preced
gener
estim
equat
analysi
conduct
compar
viral
vs
nonvir
exacerb
account
patient
experienc
type
exacerb
data
present
mean
confid
interv
statist
test
two
side
signific
appli
thirtyf
patient
chronic
p
aeruginosa
airway
infect
enrol
follow
averag
day
twentytwo
patient
total
exacerb
studi
period
maximum
exacerb
per
patient
mean
time
recent
stabl
visit
exacerb
day
exacerb
postexacerb
assess
day
patient
demograph
inform
found
tabl
sign
symptom
present
exacerb
differ
viru
nonviru
associ
exacerb
shown
fig
patient
fulfil
criteria
cf
exacerb
time
exacerb
three
patient
requir
hospit
treat
intraven
iv
antibiot
addit
patient
treat
iv
antibiot
home
treat
oral
antibiot
requir
treatment
three
exacerb
exclud
quantit
bacteri
sputum
densiti
calcul
two
patient
grow
p
aeruginosa
time
exacerb
one
sampl
insuffici
volum
fig
illustr
chang
p
aeruginosa
bacteri
densiti
sputum
collect
stabl
pulmonari
exacerb
postexacerb
assess
via
quantit
cultur
signific
chang
coloni
count
stabl
state
exacerb
mean
withinpati
differ
log
cfuml
ci
p
similarli
signific
chang
p
aeruginosa
sputum
densiti
steadi
state
exacerb
measur
pcr
mean
chang
ct
cycl
ci
p
neg
valu
indic
higher
bacteri
densiti
exacerb
sampl
stabl
sampl
signific
chang
bacteri
densiti
exacerb
postexacerb
state
mean
within
patient
chang
sputum
densiti
exacerb
postexacerb
visit
log
cfuml
ci
p
seven
patient
return
postexacerb
assess
exclud
analysi
statist
analysi
compar
chang
sputum
bacteri
densiti
quantit
cultur
chang
nucleic
acid
detect
quantit
pcr
show
moder
correl
pearson
correl
coeffici
p
thirti
exacerb
pair
sputum
taken
baselin
time
exacerb
analysi
viral
infect
baselin
could
detect
viral
dnarna
rtqpcr
sputum
one
stabl
state
sputum
sampl
coronaviru
contrast
time
exacerb
respiratori
virus
detect
sputum
np
swab
exacerb
sampl
virus
detect
rhinoviru
rsv
type
piv
type
corona
corona
three
virus
detect
np
swab
sputum
detect
np
swab
sputum
patient
found
subgroup
analysi
show
signific
differ
chang
p
aeruginosa
sputum
densiti
viral
nonvir
exacerb
measur
quantit
cultur
pcr
fig
quantit
cultur
differ
averag
chang
coloni
count
p
aeruginosa
log
cfuml
ci
p
viral
nonvir
group
pcr
ct
valu
comparison
mean
betweengroup
differ
cycl
ci
p
result
studi
suggest
bacteri
densiti
p
aeruginosa
increas
patient
present
cf
exacerb
compar
stabl
state
respiratori
virus
commonli
detect
cf
exacerb
exacerb
associ
viral
infect
character
greater
chang
bacteri
densiti
p
aeruginosa
compar
nonvir
associ
exacerb
date
studi
investig
whether
sputum
bacteri
densiti
increas
time
cf
exacerb
knowledg
three
studi
publish
recent
also
address
question
first
stressman
et
al
measur
bacteri
densiti
p
aeruginosa
time
exacerb
weekli
three
week
prior
found
chang
sputum
bacteri
densiti
second
public
carmodi
et
al
found
chang
total
p
aeruginosa
bacteri
densiti
sputum
steadi
state
exacerb
mean
time
state
day
lastli
fothergil
et
al
measur
sputum
bacteri
densiti
p
aeruginosa
qpcr
patient
twoyear
period
time
exacerb
sputum
bacteri
densiti
p
aeruginosa
consist
chang
postexacerb
bacteri
densiti
p
aeruginosa
sputum
found
decreas
multipl
studi
et
al
densiti
p
aeruginosa
sputum
decreas
log
cfug
day
antibiot
result
consist
studi
publish
tunney
et
al
found
sputum
bacteri
densiti
p
aeruginosa
decreas
immedi
follow
antibiot
therapi
return
baselin
level
day
later
final
studi
publish
regelmann
et
al
parenter
antibiot
therapi
result
signific
decreas
sputum
densiti
p
aeruginosa
howev
week
therapi
discontinu
sputum
densiti
p
aeruginosa
time
acut
exacerb
combin
studi
measur
bacteri
densiti
averag
day
postexacerb
show
chang
compar
time
exacerb
provid
evid
decreas
bacteri
densiti
sputum
cf
patient
associ
antibiot
therapi
exacerb
transient
phenomenon
second
question
sought
answer
studi
whether
presenc
viral
infect
time
cf
exacerb
influenc
bacteri
densiti
sputum
virus
well
recogn
trigger
exacerb
airway
diseas
includ
copd
asthma
cf
frequenc
viru
associ
exacerb
studi
somewhat
higher
previous
report
fig
comparison
chang
p
aeruginosa
coloni
count
stabl
exacerb
state
viral
nonvir
exacerb
report
log
cfuml
mean
chang
red
bar
nonvir
exacerb
log
cfuml
ci
mean
chang
viral
exacerb
log
cfuml
ci
consist
studi
use
sensit
viral
pcr
detect
techniqu
studi
perform
wark
et
al
adult
patient
cf
chronic
infect
p
aeruginosa
sputum
bacteri
densiti
increas
slightli
significantli
onefold
log
chang
exacerb
trigger
virus
compar
baselin
wherea
chang
sputum
bacteri
densiti
seen
nonvir
associ
exacerb
studi
show
result
studi
statist
insignific
differ
chang
sputum
densiti
p
aeruginosa
compar
viru
associ
exacerb
associ
virus
contrast
wark
studi
nonvir
exacerb
exhibit
trend
greater
increas
sputum
densiti
compar
studi
rhinoviru
frequent
viru
implic
reason
differ
result
seen
two
studi
might
due
differ
bacteria
studi
limit
patient
chronic
infect
p
aeruginosa
wherea
wark
studi
differ
result
may
also
explain
differ
sever
exacerb
studi
imprecis
relat
rel
small
sampl
size
studi
limit
first
rel
small
sampl
size
may
imped
abil
detect
signific
chang
bacteri
densiti
pulmonari
exacerb
well
differ
exacerb
associ
virus
second
effect
viral
infect
bacteri
prolifer
might
delay
occur
day
exacerb
present
clinic
patient
copd
infect
rhinoviru
peak
bacteri
densiti
day
follow
infect
rhinovirusassoci
copd
exacerb
mild
sever
patient
treat
corticosteroid
antibiot
cf
exacerb
possibl
delay
bacteri
prolifer
follow
virusassoci
exacerb
would
difficult
investig
sinc
antibiot
standard
therapi
present
rare
withheld
final
virus
appear
affect
sputum
densiti
p
aeruginosa
preclud
pathogenpathogen
interact
effect
viral
infect
bacteri
phenotyp
express
bacteri
virul
factor
exampl
studi
human
cf
bronchial
cell
coinfect
rsv
p
aeruginosa
direct
bind
rsv
p
aeruginosa
observ
p
aeruginosa
found
exhibit
increas
adher
human
cf
cell
vitro
presenc
rsv
interact
investig
studi
research
viralbacteri
interact
cf
lung
diseas
need
final
potenti
limit
patient
includ
studi
experienc
mild
pulmonari
exacerb
interestingli
studi
reid
et
al
major
patient
improv
clinic
antibiot
patient
decreas
sputum
densiti
p
aeruginosa
upon
complet
treatment
found
greatest
improv
lung
function
one
hypothesi
gener
find
might
chang
bacteri
sputum
densiti
greater
sever
exacerb
might
explain
observ
chang
inclus
mild
exacerb
conclus
studi
show
evid
signific
chang
sputum
densiti
p
aeruginosa
time
cf
exacerb
compar
stabl
state
although
exacerb
associ
viral
respiratori
tract
infect
viral
infect
acut
effect
chang
p
aeruginosa
sputum
bacteri
densiti
given
signific
cf
exacerb
work
need
determin
viral
infect
elicit
immun
respons
lead
exacerb
may
independ
p
aeruginosa
bacteri
load
cf
patient
well
investig
requir
understand
etiolog
exacerb
patient
viral
infect
sinc
increas
p
aeruginosa
bacteri
densiti
sputum
appear
respons
